AustralieFrV1, PascalFrancis, Corpus, bibRecord, 001231

Development of metronidazole-resistant lines of Blastocystis sp.

Identifieur interne : 001231 ( PascalFrancis/Corpus ); précédent : 001230; suivant : 001232

Development of metronidazole-resistant lines of Blastocystis sp.

Auteurs : L. A. Dunn ; K. S. W. Tan ; P. Vanelle ; T. Juspin ; M. D. Crozet ; T. Terme ; P. Upcroft ; J. A. Upcroft

Source :

Parasitology research : (1987) [ 0932-0113 ] ; 2012.

RBID : Pascal:12-0301228

Descripteurs français

Pascal (Inist)
- Développement, Métronidazole, Parasite, Blastocystis.

English descriptors

KwdEn :
- Development, Metronidazole, Parasite.

Abstract

Metronidazole (MTR) is frequently used for the treatment of Blastocystis infections, but with variable effectiveness, and often with treatment failures as a possible result of drug resistance. We have developed two Blastocystis MTR-resistant (MTR^R) subtype 4 WR1 lines (WR1-M4 and WR1-M5), with variable susceptibility to a panel of anti-protozoal agents including various 5-nitroimidazoles, nitazoxanide and furazolidone. WR1-M4 and WR1-M5 were developed and assessed over an 18-month period and displayed persistent MTR resistance, being more than 2.5-fold less susceptible to MTR than the parent isolate. The MTR^R lines grew with a similar g time to WR1, but were morphologically less consistent with a mixture of size. All Blastocystis isolates and the MTR^R lines were most susceptible to the 5-nitroimidazole drug ronidazole. WR1-M5 was apparently cross-resistant to satranidazole and furazolidone, and WR1-M4 was cross-resistant to nitazoxanide. These MTR^R lines now provide a valuable tool for the continued assessment of the efficacy and mechanism of action of new and established drugs against a range of Blastocystis sp. subtypes, in order to identify a universally effective drug and to facilitate understanding of the mechanisms of drug action and resistance in Blastocystis.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0932-0113`
A02	`01`			`@0 PARREZ`
A03		`1`		`@0 Parasitol. res. : (1987)`
A05				`@2 111`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Development of metronidazole-resistant lines of Blastocystis sp.`
A11	`01`	`1`		`@1 DUNN (L. A.)`
A11	`02`	`1`		`@1 TAN (K. S. W.)`
A11	`03`	`1`		`@1 VANELLE (P.)`
A11	`04`	`1`		`@1 JUSPIN (T.)`
A11	`05`	`1`		`@1 CROZET (M. D.)`
A11	`06`	`1`		`@1 TERME (T.)`
A11	`07`	`1`		`@1 UPCROFT (P.)`
A11	`08`	`1`		`@1 UPCROFT (J. A.)`
A14	`01`			`@1 Queensland Institute of Medical Research, PO Royal Brisbane Hospital @2 4029 Herston, Queensland @3 AUS @Z 1 aut. @Z 7 aut. @Z 8 aut.`
A14	`02`			`@1 Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore @2 Singapore @3 SGP @Z 2 aut.`
A14	`03`			`@1 Laboratoire de Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Universites d'Aix-Marseille I, II, III-CNRS, UMR 6264: Laboratoire Chimie Provence @2 Marseille @3 FRA @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut.`
A20				`@1 441-450`
A21				`@1 2012`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 5859 @5 354000504019920500`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 1 p.1/2`
A47	`01`	`1`		`@0 12-0301228`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Parasitology research : (1987)`
A66	`01`			`@0 DEU`
C01	`01`		`ENG`	@0 Metronidazole (MTR) is frequently used for the treatment of Blastocystis infections, but with variable effectiveness, and often with treatment failures as a possible result of drug resistance. We have developed two Blastocystis MTR-resistant (MTR^R) subtype 4 WR1 lines (WR1-M4 and WR1-M5), with variable susceptibility to a panel of anti-protozoal agents including various 5-nitroimidazoles, nitazoxanide and furazolidone. WR1-M4 and WR1-M5 were developed and assessed over an 18-month period and displayed persistent MTR resistance, being more than 2.5-fold less susceptible to MTR than the parent isolate. The MTR^R lines grew with a similar g time to WR1, but were morphologically less consistent with a mixture of size. All Blastocystis isolates and the MTR^R lines were most susceptible to the 5-nitroimidazole drug ronidazole. WR1-M5 was apparently cross-resistant to satranidazole and furazolidone, and WR1-M4 was cross-resistant to nitazoxanide. These MTR^R lines now provide a valuable tool for the continued assessment of the efficacy and mechanism of action of new and established drugs against a range of Blastocystis sp. subtypes, in order to identify a universally effective drug and to facilitate understanding of the mechanisms of drug action and resistance in Blastocystis.
C02	`01`	`X`		`@0 002A12A01`
C02	`02`	`X`		`@0 002A11`
C03	`01`	`X`	`FRE`	`@0 Développement @5 01`
C03	`01`	`X`	`ENG`	`@0 Development @5 01`
C03	`01`	`X`	`SPA`	`@0 Desarrollo @5 01`
C03	`02`	`X`	`FRE`	`@0 Métronidazole @2 NK @2 FR @5 02`
C03	`02`	`X`	`ENG`	`@0 Metronidazole @2 NK @2 FR @5 02`
C03	`02`	`X`	`SPA`	`@0 Metronidazol @2 NK @2 FR @5 02`
C03	`03`	`X`	`FRE`	`@0 Parasite @5 03`
C03	`03`	`X`	`ENG`	`@0 Parasite @5 03`
C03	`03`	`X`	`SPA`	`@0 Parásito @5 03`
C03	`04`	`X`	`FRE`	`@0 Blastocystis @4 INC @5 64`
C07	`01`	`X`	`FRE`	`@0 Lobosea @2 NS @5 26`
C07	`01`	`X`	`ENG`	`@0 Lobosea @2 NS @5 26`
C07	`01`	`X`	`SPA`	`@0 Lobosea @2 NS @5 26`
C07	`02`	`X`	`FRE`	`@0 Protozoa @2 NS`
C07	`02`	`X`	`ENG`	`@0 Protozoa @2 NS`
C07	`02`	`X`	`SPA`	`@0 Protozoa @2 NS`
C07	`03`	`X`	`FRE`	`@0 Amoebozoa @4 INC @5 32`
C07	`04`	`X`	`FRE`	`@0 Protiste @4 INC @5 33`
N21				`@1 226`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 12-0301228 INIST
ET :	Development of metronidazole-resistant lines of Blastocystis sp.
AU :	DUNN (L. A.); TAN (K. S. W.); VANELLE (P.); JUSPIN (T.); CROZET (M. D.); TERME (T.); UPCROFT (P.); UPCROFT (J. A.)
AF :	Queensland Institute of Medical Research, PO Royal Brisbane Hospital/4029 Herston, Queensland/Australie (1 aut., 7 aut., 8 aut.); Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore/Singapore/Singapour (2 aut.); Laboratoire de Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Universites d'Aix-Marseille I, II, III-CNRS, UMR 6264: Laboratoire Chimie Provence/Marseille/France (3 aut., 4 aut., 5 aut., 6 aut.)
DT :	Publication en série; Niveau analytique
SO :	Parasitology research : (1987); ISSN 0932-0113; Coden PARREZ; Allemagne; Da. 2012; Vol. 111; No. 1; Pp. 441-450; Bibl. 1 p.1/2
LA :	Anglais
EA :	Metronidazole (MTR) is frequently used for the treatment of Blastocystis infections, but with variable effectiveness, and often with treatment failures as a possible result of drug resistance. We have developed two Blastocystis MTR-resistant (MTR^R) subtype 4 WR1 lines (WR1-M4 and WR1-M5), with variable susceptibility to a panel of anti-protozoal agents including various 5-nitroimidazoles, nitazoxanide and furazolidone. WR1-M4 and WR1-M5 were developed and assessed over an 18-month period and displayed persistent MTR resistance, being more than 2.5-fold less susceptible to MTR than the parent isolate. The MTR^R lines grew with a similar g time to WR1, but were morphologically less consistent with a mixture of size. All Blastocystis isolates and the MTR^R lines were most susceptible to the 5-nitroimidazole drug ronidazole. WR1-M5 was apparently cross-resistant to satranidazole and furazolidone, and WR1-M4 was cross-resistant to nitazoxanide. These MTR^R lines now provide a valuable tool for the continued assessment of the efficacy and mechanism of action of new and established drugs against a range of Blastocystis sp. subtypes, in order to identify a universally effective drug and to facilitate understanding of the mechanisms of drug action and resistance in Blastocystis.
CC :	002A12A01; 002A11
FD :	Développement; Métronidazole; Parasite; Blastocystis
FG :	Lobosea; Protozoa; Amoebozoa; Protiste
ED :	Development; Metronidazole; Parasite
EG :	Lobosea; Protozoa
SD :	Desarrollo; Metronidazol; Parásito
LO :	INIST-5859.354000504019920500
ID :	12-0301228

Links to Exploration step

Pascal:12-0301228

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Development of metronidazole-resistant lines of Blastocystis sp.</title>
<author><name sortKey="Dunn, L A" sort="Dunn, L A" uniqKey="Dunn L" first="L. A." last="Dunn">L. A. Dunn</name>
<affiliation><inist:fA14 i1="01"><s1>Queensland Institute of Medical Research, PO Royal Brisbane Hospital</s1>
<s2>4029 Herston, Queensland</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tan, K S W" sort="Tan, K S W" uniqKey="Tan K" first="K. S. W." last="Tan">K. S. W. Tan</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore</s1>
<s2>Singapore</s2>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Vanelle, P" sort="Vanelle, P" uniqKey="Vanelle P" first="P." last="Vanelle">P. Vanelle</name>
<affiliation><inist:fA14 i1="03"><s1>Laboratoire de Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Universites d'Aix-Marseille I, II, III-CNRS, UMR 6264: Laboratoire Chimie Provence</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Juspin, T" sort="Juspin, T" uniqKey="Juspin T" first="T." last="Juspin">T. Juspin</name>
<affiliation><inist:fA14 i1="03"><s1>Laboratoire de Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Universites d'Aix-Marseille I, II, III-CNRS, UMR 6264: Laboratoire Chimie Provence</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Crozet, M D" sort="Crozet, M D" uniqKey="Crozet M" first="M. D." last="Crozet">M. D. Crozet</name>
<affiliation><inist:fA14 i1="03"><s1>Laboratoire de Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Universites d'Aix-Marseille I, II, III-CNRS, UMR 6264: Laboratoire Chimie Provence</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Terme, T" sort="Terme, T" uniqKey="Terme T" first="T." last="Terme">T. Terme</name>
<affiliation><inist:fA14 i1="03"><s1>Laboratoire de Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Universites d'Aix-Marseille I, II, III-CNRS, UMR 6264: Laboratoire Chimie Provence</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Upcroft, P" sort="Upcroft, P" uniqKey="Upcroft P" first="P." last="Upcroft">P. Upcroft</name>
<affiliation><inist:fA14 i1="01"><s1>Queensland Institute of Medical Research, PO Royal Brisbane Hospital</s1>
<s2>4029 Herston, Queensland</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Upcroft, J A" sort="Upcroft, J A" uniqKey="Upcroft J" first="J. A." last="Upcroft">J. A. Upcroft</name>
<affiliation><inist:fA14 i1="01"><s1>Queensland Institute of Medical Research, PO Royal Brisbane Hospital</s1>
<s2>4029 Herston, Queensland</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0301228</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0301228 INIST</idno>
<idno type="RBID">Pascal:12-0301228</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001231</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Development of metronidazole-resistant lines of Blastocystis sp.</title>
<author><name sortKey="Dunn, L A" sort="Dunn, L A" uniqKey="Dunn L" first="L. A." last="Dunn">L. A. Dunn</name>
<affiliation><inist:fA14 i1="01"><s1>Queensland Institute of Medical Research, PO Royal Brisbane Hospital</s1>
<s2>4029 Herston, Queensland</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tan, K S W" sort="Tan, K S W" uniqKey="Tan K" first="K. S. W." last="Tan">K. S. W. Tan</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore</s1>
<s2>Singapore</s2>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Vanelle, P" sort="Vanelle, P" uniqKey="Vanelle P" first="P." last="Vanelle">P. Vanelle</name>
<affiliation><inist:fA14 i1="03"><s1>Laboratoire de Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Universites d'Aix-Marseille I, II, III-CNRS, UMR 6264: Laboratoire Chimie Provence</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Juspin, T" sort="Juspin, T" uniqKey="Juspin T" first="T." last="Juspin">T. Juspin</name>
<affiliation><inist:fA14 i1="03"><s1>Laboratoire de Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Universites d'Aix-Marseille I, II, III-CNRS, UMR 6264: Laboratoire Chimie Provence</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Crozet, M D" sort="Crozet, M D" uniqKey="Crozet M" first="M. D." last="Crozet">M. D. Crozet</name>
<affiliation><inist:fA14 i1="03"><s1>Laboratoire de Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Universites d'Aix-Marseille I, II, III-CNRS, UMR 6264: Laboratoire Chimie Provence</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Terme, T" sort="Terme, T" uniqKey="Terme T" first="T." last="Terme">T. Terme</name>
<affiliation><inist:fA14 i1="03"><s1>Laboratoire de Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Universites d'Aix-Marseille I, II, III-CNRS, UMR 6264: Laboratoire Chimie Provence</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Upcroft, P" sort="Upcroft, P" uniqKey="Upcroft P" first="P." last="Upcroft">P. Upcroft</name>
<affiliation><inist:fA14 i1="01"><s1>Queensland Institute of Medical Research, PO Royal Brisbane Hospital</s1>
<s2>4029 Herston, Queensland</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Upcroft, J A" sort="Upcroft, J A" uniqKey="Upcroft J" first="J. A." last="Upcroft">J. A. Upcroft</name>
<affiliation><inist:fA14 i1="01"><s1>Queensland Institute of Medical Research, PO Royal Brisbane Hospital</s1>
<s2>4029 Herston, Queensland</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Parasitology research : (1987)</title>
<title level="j" type="abbreviated">Parasitol. res. : (1987)</title>
<idno type="ISSN">0932-0113</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Parasitology research : (1987)</title>
<title level="j" type="abbreviated">Parasitol. res. : (1987)</title>
<idno type="ISSN">0932-0113</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Development</term>
<term>Metronidazole</term>
<term>Parasite</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Développement</term>
<term>Métronidazole</term>
<term>Parasite</term>
<term>Blastocystis</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Metronidazole (MTR) is frequently used for the treatment of Blastocystis infections, but with variable effectiveness, and often with treatment failures as a possible result of drug resistance. We have developed two Blastocystis MTR-resistant (MTR<sup>R</sup>
) subtype 4 WR1 lines (WR1-M4 and WR1-M5), with variable susceptibility to a panel of anti-protozoal agents including various 5-nitroimidazoles, nitazoxanide and furazolidone. WR1-M4 and WR1-M5 were developed and assessed over an 18-month period and displayed persistent MTR resistance, being more than 2.5-fold less susceptible to MTR than the parent isolate. The MTR<sup>R</sup>
 lines grew with a similar g time to WR1, but were morphologically less consistent with a mixture of size. All Blastocystis isolates and the MTR<sup>R</sup>
 lines were most susceptible to the 5-nitroimidazole drug ronidazole. WR1-M5 was apparently cross-resistant to satranidazole and furazolidone, and WR1-M4 was cross-resistant to nitazoxanide. These MTR<sup>R</sup>
 lines now provide a valuable tool for the continued assessment of the efficacy and mechanism of action of new and established drugs against a range of Blastocystis sp. subtypes, in order to identify a universally effective drug and to facilitate understanding of the mechanisms of drug action and resistance in Blastocystis.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0932-0113</s0>
</fA01>
<fA02 i1="01"><s0>PARREZ</s0>
</fA02>
<fA03 i2="1"><s0>Parasitol. res. : (1987)</s0>
</fA03>
<fA05><s2>111</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Development of metronidazole-resistant lines of Blastocystis sp.</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>DUNN (L. A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>TAN (K. S. W.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>VANELLE (P.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>JUSPIN (T.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>CROZET (M. D.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>TERME (T.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>UPCROFT (P.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>UPCROFT (J. A.)</s1>
</fA11>
<fA14 i1="01"><s1>Queensland Institute of Medical Research, PO Royal Brisbane Hospital</s1>
<s2>4029 Herston, Queensland</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore</s1>
<s2>Singapore</s2>
<s3>SGP</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Laboratoire de Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Universites d'Aix-Marseille I, II, III-CNRS, UMR 6264: Laboratoire Chimie Provence</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>441-450</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>5859</s2>
<s5>354000504019920500</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1 p.1/2</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0301228</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Parasitology research : (1987)</s0>
</fA64>
<fA66 i1="01"><s0>DEU</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Metronidazole (MTR) is frequently used for the treatment of Blastocystis infections, but with variable effectiveness, and often with treatment failures as a possible result of drug resistance. We have developed two Blastocystis MTR-resistant (MTR<sup>R</sup>
) subtype 4 WR1 lines (WR1-M4 and WR1-M5), with variable susceptibility to a panel of anti-protozoal agents including various 5-nitroimidazoles, nitazoxanide and furazolidone. WR1-M4 and WR1-M5 were developed and assessed over an 18-month period and displayed persistent MTR resistance, being more than 2.5-fold less susceptible to MTR than the parent isolate. The MTR<sup>R</sup>
 lines grew with a similar g time to WR1, but were morphologically less consistent with a mixture of size. All Blastocystis isolates and the MTR<sup>R</sup>
 lines were most susceptible to the 5-nitroimidazole drug ronidazole. WR1-M5 was apparently cross-resistant to satranidazole and furazolidone, and WR1-M4 was cross-resistant to nitazoxanide. These MTR<sup>R</sup>
 lines now provide a valuable tool for the continued assessment of the efficacy and mechanism of action of new and established drugs against a range of Blastocystis sp. subtypes, in order to identify a universally effective drug and to facilitate understanding of the mechanisms of drug action and resistance in Blastocystis.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A12A01</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002A11</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Développement</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Development</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Desarrollo</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Métronidazole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Metronidazole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Metronidazol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Parasite</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Parasite</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Parásito</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Blastocystis</s0>
<s4>INC</s4>
<s5>64</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Lobosea</s0>
<s2>NS</s2>
<s5>26</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Lobosea</s0>
<s2>NS</s2>
<s5>26</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Lobosea</s0>
<s2>NS</s2>
<s5>26</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Protozoa</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Protozoa</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Protozoa</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Amoebozoa</s0>
<s4>INC</s4>
<s5>32</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Protiste</s0>
<s4>INC</s4>
<s5>33</s5>
</fC07>
<fN21><s1>226</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 12-0301228 INIST</NO>
<ET>Development of metronidazole-resistant lines of Blastocystis sp.</ET>
<AU>DUNN (L. A.); TAN (K. S. W.); VANELLE (P.); JUSPIN (T.); CROZET (M. D.); TERME (T.); UPCROFT (P.); UPCROFT (J. A.)</AU>
<AF>Queensland Institute of Medical Research, PO Royal Brisbane Hospital/4029 Herston, Queensland/Australie (1 aut., 7 aut., 8 aut.); Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore/Singapore/Singapour (2 aut.); Laboratoire de Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Universites d'Aix-Marseille I, II, III-CNRS, UMR 6264: Laboratoire Chimie Provence/Marseille/France (3 aut., 4 aut., 5 aut., 6 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Parasitology research : (1987); ISSN 0932-0113; Coden PARREZ; Allemagne; Da. 2012; Vol. 111; No. 1; Pp. 441-450; Bibl. 1 p.1/2</SO>
<LA>Anglais</LA>
<EA>Metronidazole (MTR) is frequently used for the treatment of Blastocystis infections, but with variable effectiveness, and often with treatment failures as a possible result of drug resistance. We have developed two Blastocystis MTR-resistant (MTR<sup>R</sup>
) subtype 4 WR1 lines (WR1-M4 and WR1-M5), with variable susceptibility to a panel of anti-protozoal agents including various 5-nitroimidazoles, nitazoxanide and furazolidone. WR1-M4 and WR1-M5 were developed and assessed over an 18-month period and displayed persistent MTR resistance, being more than 2.5-fold less susceptible to MTR than the parent isolate. The MTR<sup>R</sup>
 lines grew with a similar g time to WR1, but were morphologically less consistent with a mixture of size. All Blastocystis isolates and the MTR<sup>R</sup>
 lines were most susceptible to the 5-nitroimidazole drug ronidazole. WR1-M5 was apparently cross-resistant to satranidazole and furazolidone, and WR1-M4 was cross-resistant to nitazoxanide. These MTR<sup>R</sup>
 lines now provide a valuable tool for the continued assessment of the efficacy and mechanism of action of new and established drugs against a range of Blastocystis sp. subtypes, in order to identify a universally effective drug and to facilitate understanding of the mechanisms of drug action and resistance in Blastocystis.</EA>
<CC>002A12A01; 002A11</CC>
<FD>Développement; Métronidazole; Parasite; Blastocystis</FD>
<FG>Lobosea; Protozoa; Amoebozoa; Protiste</FG>
<ED>Development; Metronidazole; Parasite</ED>
<EG>Lobosea; Protozoa</EG>
<SD>Desarrollo; Metronidazol; Parásito</SD>
<LO>INIST-5859.354000504019920500</LO>
<ID>12-0301228</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001231 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001231 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:12-0301228
   |texte=   Development of metronidazole-resistant lines of Blastocystis sp.
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Development of metronidazole-resistant lines of Blastocystis sp.

Development of metronidazole-resistant lines of Blastocystis sp.

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri